{"success":true,"data":{"pressRelease":{"id":"16408","rtpr_id":"nPn7bRpr8a","ticker":"TBPH","exchange":"NASDAQ","all_tickers":["TBPH"],"title":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH","author":"PR Newswire","published_at":"2026-05-01T02:40:02.027Z","article_body":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH\n\nPR Newswire\n\nNEW YORK, April 30, 2026\n\nNEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims\non behalf of investors of Theravance Biopharma, Inc. (\"Theravance\" or the\n\"Company\") (NASDAQ: TBPH).  Such investors are advised to contact Danielle\nPeyton at newaction@pomlaw.com (mailto:newaction@pomlaw.com)  or\n646-581-9980, ext. 7980.\n\n(https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.html)\n\nThe investigation concerns whether Theravance and certain of its officers\nand/or directors have engaged in securities fraud or other unlawful business\npractices.\n\n[Click here for information about joining the class action]\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678306-6&h=1265571013&u=https%3A%2F%2Fpomlaw.com%2Flearn-more-form%3Fcompany%3DTBPH&a=%5BClick+here+for+information+about+joining+the+class+action%5D)\n\nOn March 3, 2026, Theravance issued a press release \"announc[ing] topline\nresults from the Phase 3 CYPRESS study evaluating the efficacy and safety of\nampreloxetine in patients with symptomatic neurogenic orthostatic hypotension\n(nOH) due to multiple system atrophy (MSA), a rare disease.\"  Theravance\ndisclosed that \"[t]he study did not meet its primary endpoint in the\nOrthostatic Hypotension Symptom Assessment (OHSA) composite score\" and \"[a]s\na result of this outcome, the Company has decided to wind down the\nampreloxetine program.\"\n\nOn this news, Theravance's stock price fell $4.99 per share, or 26.33%, to\nclose at $13.96 per share on March 3, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678306-6&h=1617513594&u=http%3A%2F%2Fwww.pomlaw.com%2F&a=www.pomlaw.com)\n.\n\nAttorney advertising. Prior results do not guarantee similar outcomes.\n\nCONTACT:\nDanielle Peyton\nPomerantz LLP\ndpeyton@pomlaw.com (mailto:dpeyton@pomlaw.com)\n646-581-9980 ext. 7980\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-theravance-biopharma-inc---tbph-302759717.html\n(https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-theravance-biopharma-inc---tbph-302759717.html)\n\nSOURCE Pomerantz LLP\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn7bRpr8a","title":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH","author":"PR Newswire","ticker":"TBPH","created":"2026-05-01T02:40:02.027Z","tickers":["TBPH"],"exchange":"NASDAQ","article_body":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH\n\nPR Newswire\n\nNEW YORK, April 30, 2026\n\nNEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims\non behalf of investors of Theravance Biopharma, Inc. (\"Theravance\" or the\n\"Company\") (NASDAQ: TBPH).  Such investors are advised to contact Danielle\nPeyton at newaction@pomlaw.com (mailto:newaction@pomlaw.com)  or\n646-581-9980, ext. 7980.\n\n(https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.html)\n\nThe investigation concerns whether Theravance and certain of its officers\nand/or directors have engaged in securities fraud or other unlawful business\npractices.\n\n[Click here for information about joining the class action]\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678306-6&h=1265571013&u=https%3A%2F%2Fpomlaw.com%2Flearn-more-form%3Fcompany%3DTBPH&a=%5BClick+here+for+information+about+joining+the+class+action%5D)\n\nOn March 3, 2026, Theravance issued a press release \"announc[ing] topline\nresults from the Phase 3 CYPRESS study evaluating the efficacy and safety of\nampreloxetine in patients with symptomatic neurogenic orthostatic hypotension\n(nOH) due to multiple system atrophy (MSA), a rare disease.\"  Theravance\ndisclosed that \"[t]he study did not meet its primary endpoint in the\nOrthostatic Hypotension Symptom Assessment (OHSA) composite score\" and \"[a]s\na result of this outcome, the Company has decided to wind down the\nampreloxetine program.\"\n\nOn this news, Theravance's stock price fell $4.99 per share, or 26.33%, to\nclose at $13.96 per share on March 3, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678306-6&h=1617513594&u=http%3A%2F%2Fwww.pomlaw.com%2F&a=www.pomlaw.com)\n.\n\nAttorney advertising. Prior results do not guarantee similar outcomes.\n\nCONTACT:\nDanielle Peyton\nPomerantz LLP\ndpeyton@pomlaw.com (mailto:dpeyton@pomlaw.com)\n646-581-9980 ext. 7980\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-theravance-biopharma-inc---tbph-302759717.html\n(https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-theravance-biopharma-inc---tbph-302759717.html)\n\nSOURCE Pomerantz LLP\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-01T02:40:02.06717383Z","server_sent_at_ms":1777603202067},"received_at":"2026-05-01T02:40:02.428Z","source_url":"https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-theravance-biopharma-inc---tbph-302744241.html"},"analysis":{"id":"12231","press_release_id":"16408","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Pomerantz LLP announced it is investigating claims on behalf of investors of Theravance Biopharma regarding potential securities fraud or other unlawful business practices.\n\nThe investigation focuses on the period surrounding the March 3 announcement that the Phase 3 CYPRESS study for ampreloxetine failed to meet its primary endpoint, which caused the stock to drop over 26%.\n\nThis release is a solicitation for affected investors to contact the firm; no class action has been certified by a court at this time.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc.","namedEntities":{"people":[{"name":"Danielle Peyton"}],"products":["ampreloxetine","CYPRESS"],"companies":[{"name":"Theravance Biopharma, Inc.","ticker":"TBPH","relationship":"target"},{"name":"Pomerantz LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$4.99","context":"stock price decline on March 3, 2026"},{"amount":"$13.96","context":"closing share price on March 3, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Pomerantz LLP. No new disclosure from the issuer; no certified class or settlement announced. Boilerplate investigation notice regarding prior corporate events."},"tickerRelevance":{"others":[],"primary":"TBPH"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Pomerantz LLP announced it is investigating claims on behalf of investors of Theravance Biopharma regarding potential securities fraud or other unlawful business practices.\n\nThe investigation focuses on the period surrounding the March 3 announcement that the Phase 3 CYPRESS study for ampreloxetine failed to meet its primary endpoint, which caused the stock to drop over 26%.\n\nThis release is a solicitation for affected investors to contact the firm; no class action has been certified by a court at this time.","key_figures":{},"named_entities":{"people":[{"name":"Danielle Peyton"}],"products":["ampreloxetine","CYPRESS"],"companies":[{"name":"Theravance Biopharma, Inc.","ticker":"TBPH","relationship":"target"},{"name":"Pomerantz LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$4.99","context":"stock price decline on March 3, 2026"},{"amount":"$13.96","context":"closing share price on March 3, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-01T02:43:04.451Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":31115,"modelName":"glm-4.7"}}